Nilotinib Ratiopharm (Nilotinib)

Nilotinib is a targeted tyrosine kinase inhibitor used in the management of chronic myeloid leukemia (CML).

• Chronic myeloid leukemia (chronic phase): reduces leukemic cell proliferation and achieves cytogenetic and molecular responses.
• Chronic myeloid leukemia (accelerated phase): helps control disease progression and improve survival.
• Chronic myeloid leukemia (blast crisis): provides disease control when combined with other therapies.

• Nilotinib selectively inhibits the BCR‑ABL tyrosine kinase, the oncogenic driver of chronic myeloid leukemia, while also blocking KIT and PDGFR signaling. By binding to the ATP‑binding site of these kinases, it prevents phosphorylation of downstream substrates, halting abnormal cell proliferation and inducing apoptosis of malignant clones.

Nilotinib may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Rash: mild skin irritation or redness.
• Nausea: feeling of sickness or urge to vomit.
• Diarrhea: loose or watery stools.
• Elevated liver enzymes: increase in ALT/AST levels.

Serious or Rare Side Effects

• Cardiovascular events: including arterial occlusion, heart attack, or stroke.
• Pancreatitis: inflammation of the pancreas presenting with abdominal pain.
• Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis.

When prescribing Nilotinib, clinicians should consider several safety precautions.

• Cardiac monitoring: assess cardiovascular risk and monitor for ischemic events.
• Liver function: evaluate baseline hepatic enzymes and repeat monitoring during therapy.
• Electrolyte balance: check serum potassium and magnesium levels regularly.
• Drug interactions: avoid concomitant use with strong CYP3A4 inhibitors.
• Pregnancy and lactation: contraindicated in pregnancy; advise effective contraception and avoid breastfeeding.
• Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture and light.

Nilotinib interacts with several medications that can alter its effectiveness or increase toxicity.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise Nilotinib plasma levels, increasing risk of serious adverse events.
• Proton pump inhibitors (e.g., omeprazole) taken concomitantly: can reduce absorption and lower efficacy.
• Antacids containing aluminum or magnesium: may decrease drug bioavailability.

Moderate Interactions (Monitor Closely)

• CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower Nilotinib concentrations, reducing therapeutic effect.
• Statins (e.g., simvastatin, atorvastatin): increased risk of myopathy; dose adjustment may be needed.
• Anticoagulants (e.g., warfarin): monitor INR as Nilotinib may affect coagulation parameters.